10-Q: Protalix Reports Strong Elfabrio Sales, Advances Pipeline

Protalix BioTherapeutics reports significant revenue growth driven by Elfabrio sales and reduced net loss, while advancing its pipeline and securing additional capital.

Summary

• Total revenue for the six months ended June 30, 2025, increased by 49% to $25.8 million, up from $17.2 million in the same period of 2024.
• Revenue from selling goods rose by 49% to $25.4 million, primarily due to an $8.1 million increase in sales to Chiesi and a $4.6 million increase in sales to Pfizer, partially offset by a $4.3 million decrease in sales to Fiocruz (Brazil).
• Net loss for the six months ended June 30, 2025, improved to $3.5 million, compared to a net loss of $6.8 million for the same period in 2024.
• For the three months ended June 30, 2025, the company reported a net income of $0.2 million, a significant improvement from a net loss of $2.2 million in the prior year's comparable quarter.
• Research and development expenses increased by 64% to $9.5 million for the six months ended June 30, 2025, driven by preparations for the planned Phase II clinical trial of PRX-115.
• Selling, general and administrative expenses decreased by 21% to $5.2 million for the six months ended June 30, 2025.
• Cash and cash equivalents and short-term bank deposits totaled $33.4 million as of June 30, 2025.
• The company believes its current cash and cash equivalents are sufficient to satisfy capital needs for at least 12 months from the report issuance date.
• The global market for Fabry disease is forecasted to grow at a CAGR of 7.39% from 2024-2030, reaching approximately $3.2 billion in annual sales by 2030.
• The global market for Gaucher disease is forecasted to decline at a CAGR of approximately -1.66% from 2024-2030, reaching approximately $1.7 billion in 2025.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth, particularly from its key product Elfabrio, and achieved quarterly net income, indicating improving financial health. Significant R&D investment in pipeline candidates like PRX-115 is a positive for future growth. While operating cash flow was negative, the company successfully raised capital and states sufficient liquidity for 12 months. Geopolitical risks and declining Fiocruz sales are noted but overall progress is positive.

Positives

• Significant increase in total revenue by 49% for the six months ended June 30, 2025, primarily driven by strong sales of Elfabrio to Chiesi and Elelyso to Pfizer.
• Achieved net income of $0.2 million for the three months ended June 30, 2025, indicating a positive shift in profitability for the quarter.
• Operating loss significantly reduced for the six-month period, improving from $(7.3) million in 2024 to $(3.0) million in 2025.
• Advancement of PRX-115 (for uncontrolled gout) to preparations for a Phase II clinical trial, expected to commence in the second half of 2025, following positive Phase I results demonstrating dose-dependent urate reduction and good tolerability.
• Elfabrio has received marketing approvals in multiple key regions beyond the US and EU, including Great Britain, Switzerland, Peru, Israel, Russia, Singapore, Australia, and Taiwan, expanding its commercial reach.
• The EMA validated Chiesi's Variation Submission for Elfabrio to add a 2 mg/kg every four weeks dosage, potentially offering more flexible treatment options.
• Successful capital raise of $6.8 million through the Sales Agreement and $2.4 million from warrant/option exercises during the six-month period, bolstering liquidity.
• Management believes current cash and short-term bank deposits are sufficient for at least 12 months, providing near-term financial stability.

Negatives

• Net cash used in operations was $10.3 million for the six months ended June 30, 2025, a significant decline from net cash provided by operations of $0.6 million in the prior year.
• Sales of Elelyso to Fiocruz (Brazil) significantly decreased by $4.3 million for the six months ended June 30, 2025, and were $0 for the three months ended June 30, 2025, indicating potential issues with this partnership.
• The Gaucher disease market, where Elelyso competes, is forecasted to decline at a CAGR of approximately -1.66% from 2024-2030.
• Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with ERT class labeling, which could impact market adoption.
• The BALANCE study results for Elfabrio did not support a non-inferiority claim to the comparator product due to lack of data for the non-inferiority margin, despite meeting the primary efficacy endpoint.

Risks

• Risks related to the commercialization of Elfabrio, including market acceptance, competition, reimbursement, and regulatory actions, particularly due to the boxed warning.
• Possible disruption of operations due to the ongoing war in Israel and regional conflicts, which could affect regulatory authorities, suppliers, partners, clinical trial sites, distributors, and customers.
• Risks related to the regulatory approval and commercial success of other product candidates.
• Failure or delay in the commencement or completion of preclinical studies and clinical trials due to factors like slow patient recruitment, unforeseen safety issues, dosing issues, lack of effectiveness, or insufficient funding.
• Delays in approval or potential rejection of applications filed with the FDA, EMA, or other health regulatory authorities for product candidates.
• Risks associated with global conditions and developments such as new tariffs, trade restrictions, supply chain challenges, inflationary environment, tight labor market, and instability in the banking industry.
• The risk that the results of clinical trials will not support applicable claims of safety or efficacy, or that product candidates will have undesirable side effects.
• Risks relating to managing relationships with collaborators, distributors, or partners, including Pfizer and Chiesi.
• Risks related to the amount and sufficiency of cash and cash equivalents and short-term bank deposits.
• Risks relating to the compliance of Fiocruz with its purchase obligations under the Brazil Agreement, which may lead to termination of the agreement.
• Risk of significant lawsuits, including stockholder litigation.
• Dependence on performance by third-party providers of services and supplies, including clinical trial services.
• The inherent risks and uncertainties in developing drug platforms and products.
• The impact of development of competing therapies and/or technologies by other companies.
• Potential product liability risks and risks of securing adequate levels of related insurance coverage.
• The possibility of infringing third-party patents or other intellectual property rights and the uncertainty of obtaining and enforcing intellectual property rights.
• Risks relating to changes in healthcare laws, rules, and regulations in the United States or elsewhere.
• The impact of Section 174 of the U.S. Tax Cuts and Jobs Act of 2017, which requires capitalization and amortization of R&D expenses for tax purposes, although new legislation (HR1) restores deductibility for domestic R&D from 2025.

Future Outlook

The company expects to continue incurring significant and increasing research and development expenses as it advances its product candidates into more advanced stages of preclinical and clinical trials, particularly with the planned Phase II clinical trial of PRX-115. While revenues from Elfabrio and Elelyso are expected to increase, they may not be sufficient to fund all expenditures, potentially requiring additional financing. The company is also evaluating the impact of new U.S. tax legislation (HR1) on its financial statements, which restores deductibility for domestic research expenditures starting in 2025. The company continues to evaluate potential strategic marketing partnerships and collaboration programs.

Management Comments

• "We expect to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates."
• "We believe that its cash and cash equivalents and short-term bank deposits as of June 30, 2025, are sufficient to satisfy the Companys capital needs for at least 12 months from the date that these financial statements are issued."
• "We expect to finance our future cash needs through sales of Elfabrio and Elelyso, corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings."

Industry Context

Protalix operates in the biopharmaceutical sector, specializing in recombinant therapeutic proteins for rare and orphan diseases, leveraging its proprietary ProCellEx plant cell-based protein expression system. The company's key products, Elfabrio (Fabry disease) and Elelyso (Gaucher disease), address Lysosomal Storage Disorders (LSDs). The Fabry disease market is projected for significant growth, indicating a favorable environment for Elfabrio. In contrast, the Gaucher disease market is forecasted to decline, suggesting potential challenges for Elelyso's future sales. The company's focus on new early-stage candidates for high unmet needs, including renal diseases, aligns with broader industry trends towards precision medicine and addressing underserved patient populations. The advancement of PRX-115 for uncontrolled gout positions the company in a large inflammatory arthritis market with existing therapies that have significant side effects or compliance issues, suggesting a potential niche for a new, well-tolerated treatment.

Comparison to Industry Standards

• Elfabrio (pegunigalsidase alfa) is a new entrant in the Fabry disease ERT market, competing with established therapies like Sanofi's Fabrazyme (agalsidase beta) and Shire's (Takeda's) Replagal (agalsidase alfa). While the BALANCE study met its primary efficacy endpoint, it did not support a non-inferiority claim to agalsidase beta, which could be a competitive disadvantage in some clinical settings.
• Elelyso (taliglucerase alfa) competes in the Gaucher disease ERT market against Sanofi's Cerezyme and Shire's (Takeda's) Vpriv. Elelyso is noted as the only alternative ERT treatment to Cerezyme and Vpriv, and in Brazil, it is the therapy of choice for newly diagnosed patients, indicating a strong position in that specific market.
• PRX-115 for uncontrolled gout aims to compete with existing recombinant uricases like Horizon Therapeutics' Krystexxa (pegloticase) and Sanofi's Elitek (rasburicase). Krystexxa has a black box warning for anaphylaxis and is no longer marketed in the EU, suggesting a significant unmet need for safer, effective alternatives, which PRX-115's Phase I tolerability data could address. The potential for a wide dosing interval for PRX-115 could offer a compliance advantage over current therapies.

Management Changes

Corporate Governance

Legal Proceedings

• Not involved in any material legal proceedings.

Stakeholder Impact

• Shareholders: Potential for future dilution due to ongoing 'at-the-market' equity offerings, but also benefit from improved financial performance and pipeline progress. Stock options and warrants exercises impact share count.
• Patients: Continued access to Elelyso and Elfabrio, with potential for new treatment options from the pipeline (PRX-115, PRX-119) addressing unmet medical needs.
• Employees: Share-based compensation plans continue, and a key management change (CFO) has been announced with a transition plan.
• Customers/Partners (Chiesi, Pfizer, Fiocruz): Strong sales growth with Chiesi and Pfizer, but a significant decline in sales to Fiocruz in Brazil, indicating potential shifts in partnership dynamics or market share.
• Creditors: Repayment of 2024 Notes in full in September 2024 reduces debt obligations and associated financial limitations.

Next Steps

• Commence a Phase II clinical trial of PRX-115 for uncontrolled gout in the second half of 2025.
• Continue recruitment for the Pediatric FLY Study (Elfabrio) and the Japanese RISE Study (Elfabrio).
• Evaluate the impact of the new U.S. tax reform legislation (HR1) on consolidated financial statements.
• Continue to incur significant and increasing research and development expenses for product candidates.
• Negotiate certain manufacturing related matters with Chiesi as per the May 2021 amendment to the Chiesi Agreements.

Key Dates

Recommendation

The company shows strong revenue growth driven by its commercial products, particularly Elfabrio, and has significantly improved its net loss, even achieving net income in the most recent quarter. The advancement of its pipeline, especially PRX-115 to Phase II, indicates future growth potential. While the company has negative operating cash flow, it has successfully raised capital and asserts sufficient liquidity for the next 12 months. However, the decline in sales to Fiocruz and the inherent risks of biotech development, including geopolitical risks in Israel, warrant a cautious approach. For existing investors, holding is advised to observe continued commercialization success and pipeline progression. For new investors, a 'hold' suggests waiting for more consistent positive operating cash flow or further de-risking of the pipeline, despite the positive revenue trends.

Keywords

Biopharmaceutical, Fabry disease, Gaucher disease, Elfabrio, Elelyso, Enzyme Replacement Therapy, ERT, ProCellEx, Rare diseases, Orphan drugs, Clinical trials, PRX-115, Gout, PRX-119, NETs-related diseases, SEC filing, 10-Q, Biotechnology, Pharmaceuticals